Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2011

Tsai Chun-Ming, Chen Jen-Ting, Stewart David J, Chiu Chao-Hua, Lai Chun-Liang, Hsiao Shih-Yin, Chen Yuh-Min, Chang Kuo-Ting

Abstract excerpt

INTRODUCTION: Four phase III randomized trials adding epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors to standard chemotherapeutics in patients with advanced non-small cell lung cancer (NSCLC) have failed to show benefits. The mechanism of these failures was examined. METHODS: Fifteen previously untreated NSCLC cell lines were simultaneously treated with gefitinib plus cisplatin. Three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Paclitaxel
Share to Adenocarcinoma, Bronchiolo-Alveolar

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Large Cell

Share to Cisplatin

Share to Clinical Trials, Phase III as Topic

Share to Gefitinib

Share to Randomized Controlled Trials as Topic

Share to Treatment Failure

Source

Identifiers

PMID: 21258258
DOI: 10.1097/JTO.0b013e3182021ff5

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?PMID 21258258Read ↗

Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.Semantic proximity Read ↗

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.Semantic proximity Read ↗

Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.Semantic proximity Read ↗

The effect of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells.Semantic proximity Read ↗

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.Semantic proximity Read ↗

Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: Why clinical trials have failed and how they could succeedSemantic proximity Read ↗

Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.Semantic proximity Read ↗

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.Semantic proximity Read ↗

Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.Semantic proximity Read ↗

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell linesSemantic proximity Read ↗

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell linesSemantic proximity Read ↗

5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.